Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DGPR1008 Phase I/IIa
NCT07101354Phase 1Completed
- Sponsor
- Qingdao Niu Haitao Medical Technology
- Start
- Jun 2024
- Primary completion
- Jul 2024
- Modality
- Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of DGPR1008 in prostate cancer (PCa) (5 arms), sponsored by Qingdao Niu Haitao Medical Technology. Primary endpoints: Incidence of Treatment-Emergent Adverse Events, Number of participants with abnormal vital signs and 2 more. Started Jun 2024; status: completed.
02
Drugs
DGPR1008
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07101354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07101354.